Our preclinical studies in migraine-model rats demonstrated that SSF significantly reduced serum and trigeminal ganglion (TG) levels of CGRP while elevating 5-hydroxytryptamine (5-HT) concentrations, with concomitant downregulation of nuclear factor-kappa B (NF-κB) and cyclooxygenase-2 (COX-2) protein expression in TG tissues, thereby ameliorating neurogenic inflammation (19). The gene discussed is PTGS2; the disease is migraine disorder.